Observational Prospective Study to Determine the Evolution of the Symptomatic Profile of Metastatic Non-Small Cell Lung Cancer (NSCLC) Patients and Its Relation to the Control of the Disease

Full copyright for enhanced digital features is owned by the authors. Article full text The full text of this article can be found here. Provide enhanced digital features for this article If you are an author of this publication and would like to provide additional enhanced digital features for your article then please contact [email protected]. The journal offers a range of additional features designed to increase visibility and readership. All features will be thoroughly peer reviewed to ensure the content is of the highest scientific standard and all features are marked as ‘peer reviewed’ to ensure readers are aware that the content has been reviewed to the same level as the articles they are being presented alongside. Moreover, all sponsorship and disclosure information is included to provide complete transparency and adherence to good publication practices. This ensures that however the content is reached the reader has a full understanding of its origin. No fees are charged for hosting additional open access content. Other enhanced features include, but are not limited to: • Slide decks • Videos and animations • Audio abstracts • Audio slides</p

Supplemental Figure 2 from Immunohistochemical Loss of LKB1 Is a Biomarker for More Aggressive Biology in <i>KRAS</i>-Mutant Lung Adenocarcinoma

Supplemental Figure 2. A, KRAS G12C mutation is the most frequently mutated in smokers while G12D is most common in never-smokers. B and C, Never-smokers were significantly more likely than former or current smokers to have a transition mutation (G>A) rather than transversion mutations known to be smoking-related (G>T or G>C).</p

Supplemental Figure 1 from Immunohistochemical Loss of LKB1 Is a Biomarker for More Aggressive Biology in <i>KRAS</i>-Mutant Lung Adenocarcinoma

Supplemental Figure 1. A, OS in stage IV KRAS-mutant NSCLC according to KRAS tranversion or transition mutations and LKB1 status. B, OS by different KRAS mutations (G12C vs. G12D)</p

Supp. Table 4 from Immunohistochemical Loss of LKB1 Is a Biomarker for More Aggressive Biology in <i>KRAS</i>-Mutant Lung Adenocarcinoma

Table S4. LKB1 patient characteristics in KRAS mutant patients (n=148)*</p

Supp. Table 1 from Immunohistochemical Loss of LKB1 Is a Biomarker for More Aggressive Biology in <i>KRAS</i>-Mutant Lung Adenocarcinoma

Supplementary Table S1. KRAS mutant NSCLC patients' characteristics (n=514)</p

Supp. Table 2 from Immunohistochemical Loss of LKB1 Is a Biomarker for More Aggressive Biology in <i>KRAS</i>-Mutant Lung Adenocarcinoma

Supplementary Table S2. Panel of cancer cell lines with known LKB1 status tested for LKB1 IHC.</p

Supp. Table 3 from Immunohistochemical Loss of LKB1 Is a Biomarker for More Aggressive Biology in <i>KRAS</i>-Mutant Lung Adenocarcinoma

Supplementary Table S3. List of LKB1 mutant lung adenocarcinoma specimens by OncoMap tested for LKB1 IHC.</p

Table S1 from Response Heterogeneity of EGFR and HER2 Exon 20 Insertions to Covalent EGFR and HER2 Inhibitors

Supplemental Table 1.</p

Supplemental Figure Legends from Response Heterogeneity of EGFR and HER2 Exon 20 Insertions to Covalent EGFR and HER2 Inhibitors

Figure legends for all supplemental figures</p

All supplemental Figures from Response Heterogeneity of EGFR and HER2 Exon 20 Insertions to Covalent EGFR and HER2 Inhibitors

Figure S1. Fifty percent (50%) inhibitory concentration of neratinib, afatinib and dacomitinib in Ba/F3 cells expressing different EGFR or HER2 exon 20 insertion mutations and the EGFR exon 20 insertion patient derived cell lines. to second generation EGFR-TKIs; Figure S2. Efficacy of neratinib, afatinib or dacomitinib against HER2 exon 20 insertion mutants measured in a soft agar assay; Figure S3. Patient derived EGFR exon 20 insertion cell lines; Figure S4. Comparison of amino acid sequences of exon 20 of EGFR to HER2.</p